Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension

American Journal of Psychiatry

Volumn 166, Issue 3, 2009, Pages 320-328

  Toh, Sengwee ^a   Mitchell, Allen A ^b   Louik, Carol ^b   Werler, Martha M ^b   Chambers, Christina D ^b   Hernández Díaz, Sonia ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MOOD DISORDER; PREECLAMPSIA; PRENATAL EXPOSURE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; BLOOD PRESSURE; DEMOGRAPHY; DEPRESSIVE DISORDER, MAJOR; FEMALE; FETAL DEVELOPMENT; HEALTH STATUS; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PRE-ECLAMPSIA; PREGNANCY; PREVALENCE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 62949111191     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.08060817     Document Type: Article

References (52)

1. Evans J, Heron J, Francomb H, Oke S, Golding J: Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323:257-260
2. Gotlib IH, Whiffen VE, Mount JH, Milne K, Cordy Nl: Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol 1989; 57:269-274
3. Cooper WO, Willy ME, Pont SJ, Ray WA: Increasing use of antide pressants in pregnancy. Am J Obstet Gynecol 2007; 196:544e1-e5
4. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Bou-dreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R: Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198:194e1-e5
5. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G: Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49:726-735
6. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ,Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM,Loughead A, Vitonis AF, Stowe ZN: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295:499-507
7. Hallberg P, Sjoblom V: The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005; 25:59-73
8. Malm H, Klaukka T, Neuvonen PJ: Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106:1289-1296
9. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, Gardner A, Horn M, Koren G: Pregnancy outcome following first-trimester exposure to fluoxetine. JAMA 1993; 269:2246-2248
10. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, TheisJG, Kulin N, Koren G: Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336:258-262
11. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibi-tors: a prospective controlled multicenter study. JAMA 1998; 279:609-610
12. Suri R, Altshuler L, Hendrick V, Rasgon N, Lee E, MintzJ: The impact of depression and fluoxetine treatment on obstetrical outome. Arch Worn ens Ment Health 2004; 7:193-200
13. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA:First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356:2675- 2683
14. Alwan S, ReefhuisJ, Rasmussen SA, Olney RS, Friedman JM: Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356:2684-2692
15. ColeJA, Ephross SA, Cosmatos IS, Walker AM: Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1075-1085
16. Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sorensen HT: Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17:701-704
17. Chambers CD, Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579-587
18. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010-1015
19. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Piatt R: Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007; 16:1086-1094
20. Kallen B: Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158:312-316
21. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, Walker M: Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194:961-966
22. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63:898-906
23. Costei AM, Kozer E, Ho T, Ito S, Koren G: Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156:1129-1132
24. Roberts JM: Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16:5-15
25. MacKay AP, Berg CJ, Atrash HK: Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001; 97: 533-538
26. Klonoff-Cohen HS, Cross JL, Pieper CF: Job stress and preeclampsia. Epidemiology 1996; 7:245-249
27. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O: Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95:487-490
28. Qiu C, Sanchez SE, Lam N, Garcia P, Williams MA: Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study. BMC Womens Health 2007; 7:15
29. Bolte AC, van Geijn HP, Dekker GA: Pathophysiology of preeclampsia and the role of serotonin. Eur J Obstet Gynecol Reprod Biol 2001; 95:12-21
30. Skop BP, Brown TM: Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.Psyrhnsomatics 1996 37-12-16
31. Mitchell AA, Cottier LB, Shapiro S: Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986; 123:670-676
32. Walker JJ: Pre-eclampsia. Lancet 2000; 356:1260-1265
33. Myatt L, Miodovnik M: Prediction of preeclampsia. Semin Perinatal 1999; 23:45-57
34. Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R: Risk factors and clinical manifestations of pre-eclampsia. BJOG 2000; 107:1410-1416
35. Ness RB, Roberts JM: Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996; 175:1365-1370
36. Mills JL, DerSimonian R, Raymond E, Morrow JD, Roberts LJ 2nd, Clemens JD, Hauth JC, Catalano P, Sibai B, Curet LB, Levine RJ: Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA 1999; 282:356-362
37. CLASP (Collaborative Low-Dose Aspirin Study in Pregnancy) Collaborative Group: CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9,364 pregnant women. Lancet 1994; 343:619-629
38. Sibai BM, Mercer B, Sarinoglu C: Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165(5 pt 1):1408-1412
39. HigginsJR, de Swiet M: Blood-pressure measurement and classification in pregnancy. Lancet 2001; 357:131-135
40. Bjoro K, Stray-Pedersen S: In vitro perfusion studies on human umbilical arteries, I: vasoactive effects of serotonin, PGF2 alpha and PGE2. Acta Obstet Gynecol Scand 1986; 65:351-355
41. Haugen G, Bjoro K, Stray-Pedersen S: Vasoactive effects of intra- and extravascular serotonin, PGE2 and PGF2 alpha in human umbilical arteries. Gynecol Obstet Invest 1991; 31:208-212
42. Abman SH: New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Pediatr Pulmonol Suppl 1999; 18:201-204
43. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M: Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 1999; 42:2561- 2568
44. Finkel MS, Laghrissi-Thode F, Pollock BG, RongJ: Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32:653-658
45. Thase ME: Effects of venlafaxine on blood pressure: a metaanalysis of original data from 3,744 depressed patients. J Clin Psychiatry 1998; 59:502-508
46. Hernandez-Diaz S, Werler MM, Mitchell AA: Gestational hypertension in pregnancies supported by infertility treatments: role of infertility, treatments, and multiple gestations. Fertil Steril 2007; 88:438-445
47. Wallis AB, Saftlas AF, Hsia J, Atrash HK: Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008; 21:521-526
48. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, Monsen AL, Ueland PM: Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine Study. Am J Clin Nutr 2000; 71:962-968
49. Conde-Agudelo A, Althabe F, Belizan JM, Kafury-Goeta AC: Cigarette smoking during pregnancy and risk of preeclampsia: asystematic review. Am J Obstet Gynecol 1999; 181:1026-1035
50. Toh S, Mitchell AA, Werler MM, Hernandez-Diaz S: Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 2008; 167:633-640
51. Sibai B, Marcel Dekker G, Kupferminc M: Pre-eclampsia. Lancet 2005; 365:785-799
52. Cohen LS, Rosenbaum JF: Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 1998; 59(suppl 2): 18-28